Gonzalo Alberto Peralta-Jiménez

Gonzalo Alberto Peralta-Jiménez

Auto-generated profile, based on publicly available information

Gonzalo Alberto Peralta-Jiménez

Arica and Parinacota Health Service, Subdirectorate of Healthcare Management, Arica, Chile

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2021 in International Journal of Sexual Health
Verified
Journal Article
Closed access
CCCarolina Alexandra Adelina Chambi-Martínez
Carolina Alexandra Adelina Chambi-Martínez
EMEsteban Moraga-Escobar
Esteban Moraga-Escobar
GPGonzalo Alberto Peralta-Jiménez
Gonzalo Alberto Peralta-Jiménez
AVAldo Vera-Calzaretta
Aldo Vera-Calzaretta
JBJaime Barrientos
Jaime Barrientos
DPDarío Páez
Darío Páez
To compare the relationships between emotional symptomatology and perceived social support according to gender identity and sexual orientation in LGBTQ+ university students.322 Chilean LGBTQ+ colle...

1 July 2025 in Diabetes, Metabolic Syndrome and Obesity
Verified
Journal Article
Open access
PDF file
JRJovana Ristic
Jovana Ristic
SKSena Kodalak
Sena Kodalak
GPGonzalo Alberto Peralta-Jiménez
Gonzalo Alberto Peralta-Jiménez
MLMaria Fernanda Moura de Lima
Maria Fernanda Moura de Lima
MKMarijana Kovacevic
Marijana Kovacevic
TNTatjana Nikolić
Tatjana Nikolić
Purpose: Diabetic kidney disease (DKD) significantly affects health and healthcare costs due to chronic kidney disease complications. Given asprosin’s potential as a biomarker for disease progression, we conducted the first systematic review and meta-analysis on its relationship with DKD in adults with type 2 diabetes mellitus (T2DM). Methods: PubMed, Embase, Cochrane, and Web of Science were systematically searched. Standard mean differences (SMD) with 95% confidence intervals (CI) and Fisher’s Z transformation were used to examine the relationship between asprosin and DKD. The risk of bias was evaluated using the Newcastle-Ottawa Scale (NOS) and its version for cross-sectional studies. Heterogeneity (I² > 50%) was analyzed with a random-effects model. Results: Six studies (n = 1340) were included. Meta-analysis results indicated that T2DM patients with DKD (micro/macroalbuminuria) had significantly higher circulating asprosin levels than normoalbuminuric T2DM patients (SMD: 1.5, 95% CI: 0.69– 2.32, p = 0.0003). Meta-analysis of correlation revealed a positive association of asprosin with urinary albumin excretion ratio (UACR) (Fisher’s Z = 0.4; 95% CI: 0.240– 0.554, p < 0.001) and body mass index (BMI) (Fisher’s Z = 0.17; 95% CI: 0.036– 0.301, p = 0.013), and a negative association with estimated glomerular filtration rate (eGFR) (Fisher’s Z = − 0.35; 95% CI: − 0.471 to − 0.239, p < 0.001). Conclusion: Asprosin is elevated in T2DM patients with pre-DKD (early stage DKD) and DKD and correlates with key markers of disease severity. Additional research is required to better understand the pathophysiological mechanisms of asprosin and its role in DKD.